22/10/2026 AbbVie’s lutikizumab met the primary endpoint in a Ph3 study for HS AbbVie’s lutikizumab met the primary endpoint in a Ph3 study for HS (Ref) AbbVie announced positive topline results from the Ph3 INTREPID trial evaluating lutikizumab (IL-1α/1β antagonist) in adults and adolescents with moderate to severe hidradenitis suppurativa (HS). The study met its primary endpoint of HiSCR75 at Week 16 as well as 8 ranked secondary endpoints, including improvement in HS-rel

21/10/2026 Ultomiris received US FDA accelerated approval for primary immunoglobulin A nephropathy Ultomiris received US FDA accelerated approval for primary immunoglobulin A nephropathy (Ref) AstraZeneca’s Ultomiris (ravulizumab; C5 complement inhibitor) received US FDA accelerated approval to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of disease progression. The FDA granted the approval after a Priority Review, based on prespecifie

16/10/2026 US FDA approved Roche’s satralizumab for TED US FDA approved UCB’s zilucoplan autoinjector adults with gMG Novartis halted a mid-stage Fablhalta study in lupus nephritis US FDA approved Roche’s satralizumab for TED (Ref) Roche’s Enspryng® (satralizumab; IL-6R inhibitor) received US FDA approval as the first and only at-home subcutaneous treatment for adults with thyroid eye disease (TED).The approval was based on Ph3, SatraGO-1 and SatraGO -2 studies. SatraGO-2 sho

13/10/2026 SAB BIO received US FDA Fast Track Designation for SAB-142 in stage 3 T1D Legacy Healthcare received US FDA Breakthrough Therapy Designation for CINAINU® (LH-8) in alopecia areata Evergreen Therapeutics received FDA Fast Track Designation for EG-501 in NPSLE-CI SAB BIO received US FDA Fast Track Designation for SAB-142 in stage 3 T1D (Ref) SAB Biotherapeutics’ SAB-142 received US FDA Fast Track Designation for treatment of new-onset Stage 3 Type 1 diabetes (T1D). T

09/10/2026 Johnson & Johnson reported 2-year data for icotrokinra in plaque PsO Alumis reported new Phase 3 data for envudeucitinib in plaque PsO Johnson & Johnson reported 2-year data for icotrokinra in plaque PsO (Ref) Johnson & Johnson reported 2-year Phase 3, ICONIC-LEAD/ NCT06095115 data for ICOTYDE® (icotrokinra; IL-23 receptor antagonist) in patients aged ≥12 years with moderate-to-severe plaque psoriasis (PsO).  Endpoint Results Timepoint PASI 90 ≥72% At Wk 12 IGA 0/

02/10/2026 Biogen reported 52-week Phase 2 data for litifilimab in CLE Biogen reported 52-week Phase 2 data for litifilimab in CLE (Ref) Biogen reported 52-week results from the Phase 2 portion (Part A) of the ongoing Phase 2/3 AMETHYST study of litifilimab (BIIB059; anti-BDCA2 mAb) showing continued improvement in cutaneous lupus erythematosus (CLE). 27.2% of patients achieved clear or almost clear skin (CLA-IGA 0–1) at Week 52, while 28.8% achieved CLASI-70. Patients who